Poly Medicure Limited

NSEI:POLYMED Voorraadrapport

Marktkapitalisatie: ₹248.0b

Poly Medicure Beheer

Beheer criteriumcontroles 2/4

De CEO Poly Medicure is Himanshu Baid, benoemd in Sep1995, heeft een ambtstermijn van 29.67 jaar. De totale jaarlijkse vergoeding van { bedraagt ₹ 171.78M, bestaande uit 33.6% salaris en 66.4% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 11.59% van de aandelen van het bedrijf, ter waarde ₹ 28.75B. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 6.9 jaar en 7 jaar.

Belangrijke informatie

Himanshu Baid

Algemeen directeur

₹171.8m

Totale compensatie

Percentage CEO-salaris33.64%
Dienstverband CEO29.7yrs
Eigendom CEO11.6%
Management gemiddelde ambtstermijn6.9yrs
Gemiddelde ambtstermijn bestuur7yrs

Recente managementupdates

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 20
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 22
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Recent updates

Poly Medicure's (NSE:POLYMED) Earnings Are Weaker Than They Seem

May 14
Poly Medicure's (NSE:POLYMED) Earnings Are Weaker Than They Seem

Market Participants Recognise Poly Medicure Limited's (NSE:POLYMED) Revenues Pushing Shares 25% Higher

May 06
Market Participants Recognise Poly Medicure Limited's (NSE:POLYMED) Revenues Pushing Shares 25% Higher

Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?

Apr 13
Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?

Some Shareholders Feeling Restless Over Poly Medicure Limited's (NSE:POLYMED) P/E Ratio

Feb 22
Some Shareholders Feeling Restless Over Poly Medicure Limited's (NSE:POLYMED) P/E Ratio

Poly Medicure Limited (NSE:POLYMED) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 06
Poly Medicure Limited (NSE:POLYMED) Just Reported Third-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?

Poly Medicure's (NSE:POLYMED) Returns On Capital Not Reflecting Well On The Business

Jan 28
Poly Medicure's (NSE:POLYMED) Returns On Capital Not Reflecting Well On The Business

Does Poly Medicure (NSE:POLYMED) Have A Healthy Balance Sheet?

Dec 28
Does Poly Medicure (NSE:POLYMED) Have A Healthy Balance Sheet?

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Makes An Interesting Case

Dec 10
With EPS Growth And More, Poly Medicure (NSE:POLYMED) Makes An Interesting Case

Why Investors Shouldn't Be Surprised By Poly Medicure Limited's (NSE:POLYMED) 33% Share Price Surge

Nov 02
Why Investors Shouldn't Be Surprised By Poly Medicure Limited's (NSE:POLYMED) 33% Share Price Surge

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 20
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00

Sep 14
Poly Medicure (NSE:POLYMED) Will Pay A Dividend Of ₹3.00

After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar

Sep 06
After Leaping 41% Poly Medicure Limited (NSE:POLYMED) Shares Are Not Flying Under The Radar

Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet

Aug 14
Poly Medicure (NSE:POLYMED) Has A Pretty Healthy Balance Sheet

Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138

Jul 27
Earnings Update: Here's Why Analysts Just Lifted Their Poly Medicure Limited (NSE:POLYMED) Price Target To ₹2,138

Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)

Jul 11
Investors Still Waiting For A Pull Back In Poly Medicure Limited (NSE:POLYMED)

Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations

May 25
Poly Medicure's (NSE:POLYMED) Promising Earnings May Rest On Soft Foundations

Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital

May 12
Why You Should Care About Poly Medicure's (NSE:POLYMED) Strong Returns On Capital

Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up

Mar 23
Poly Medicure Limited's (NSE:POLYMED) Share Price Not Quite Adding Up

Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today

Feb 15
Here's Why We Think Poly Medicure (NSE:POLYMED) Might Deserve Your Attention Today

Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Jan 16
Poly Medicure (NSE:POLYMED) Seems To Use Debt Quite Sensibly

Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?

Nov 14
Is Now The Time To Put Poly Medicure (NSE:POLYMED) On Your Watchlist?

Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward

Oct 24
Poly Medicure (NSE:POLYMED) Has More To Do To Multiply In Value Going Forward

Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Sep 22
Shareholders Will Probably Hold Off On Increasing Poly Medicure Limited's (NSE:POLYMED) CEO Compensation For The Time Being

Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00

Sep 08
Poly Medicure (NSE:POLYMED) Is Increasing Its Dividend To ₹3.00

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Aug 12
Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching

Jul 13
Here's Why We Think Poly Medicure (NSE:POLYMED) Is Well Worth Watching

Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return

Jun 16
Poly Medicure (NSE:POLYMED) Is Reinvesting At Lower Rates Of Return

Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital

Mar 02
Be Wary Of Poly Medicure (NSE:POLYMED) And Its Returns On Capital

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Feb 14
We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal

Oct 16
Capital Allocation Trends At Poly Medicure (NSE:POLYMED) Aren't Ideal

We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Sep 28
We Think Poly Medicure (NSE:POLYMED) Can Stay On Top Of Its Debt

Poly Medicure (NSE:POLYMED) Has Affirmed Its Dividend Of ₹2.50

Sep 08
Poly Medicure (NSE:POLYMED) Has Affirmed Its Dividend Of ₹2.50

Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

Jun 25
Here's Why Poly Medicure (NSE:POLYMED) Can Manage Its Debt Responsibly

A Look At The Intrinsic Value Of Poly Medicure Limited (NSE:POLYMED)

Jun 07
A Look At The Intrinsic Value Of Poly Medicure Limited (NSE:POLYMED)

Poly Medicure (NSE:POLYMED) Will Want To Turn Around Its Return Trends

May 23
Poly Medicure (NSE:POLYMED) Will Want To Turn Around Its Return Trends

With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

Feb 23
With EPS Growth And More, Poly Medicure (NSE:POLYMED) Is Interesting

There Are Reasons To Feel Uneasy About Poly Medicure's (NSE:POLYMED) Returns On Capital

Feb 04
There Are Reasons To Feel Uneasy About Poly Medicure's (NSE:POLYMED) Returns On Capital

Analyse CEO-vergoeding

Hoe is Himanshu Baid's beloning veranderd ten opzichte van Poly Medicure's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Mar 31 2025n/an/a

₹3b

Dec 31 2024n/an/a

₹3b

Sep 30 2024n/an/a

₹3b

Jun 30 2024n/an/a

₹3b

Mar 31 2024₹172m₹58m

₹3b

Dec 31 2023n/an/a

₹2b

Sep 30 2023n/an/a

₹2b

Jun 30 2023n/an/a

₹2b

Mar 31 2023₹130m₹55m

₹2b

Dec 31 2022n/an/a

₹2b

Sep 30 2022n/an/a

₹1b

Jun 30 2022n/an/a

₹1b

Mar 31 2022₹107m₹49m

₹1b

Dec 31 2021n/an/a

₹1b

Sep 30 2021n/an/a

₹1b

Jun 30 2021n/an/a

₹1b

Mar 31 2021₹92m₹44m

₹1b

Dec 31 2020n/an/a

₹1b

Sep 30 2020n/an/a

₹1b

Jun 30 2020n/an/a

₹1b

Mar 31 2020₹62m₹35m

₹959m

Dec 31 2019n/an/a

₹947m

Sep 30 2019n/an/a

₹858m

Jun 30 2019n/an/a

₹719m

Mar 31 2019₹44m₹14m

₹654m

Compensatie versus markt: De totale vergoeding ($USD 2.00M ) Himanshu } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 570.30K ).

Compensatie versus inkomsten: De vergoeding van Himanshu is het afgelopen jaar met meer dan 20% gestegen.

CEO

Himanshu Baid (56 yo)

29.7yrs
Tenure
₹171,781,000
Compensatie

Mr. Himanshu Baid has been the Managing Director of Poly Medicure Limited since September 20, 1995 and serves as Chief Executive Officer. Mr. Baid is an Electronics Engineer and has experience in respect t...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Himanshu Baid
CEO, MD & Director29.7yrs₹171.78m11.59%
₹ 28.7b
Jugal Baid
Founder & Non Executive Directorno data₹1.43m2.25%
₹ 5.6b
Naresh Vijayvergiya
Chief Financial Officer3.8yrs₹11.21mgeen gegevens
Avinash Chandra
Company Secretary & Compliance Officer10yrs₹1.88mgeen gegevens
Rishi Baid
Joint MD & Executive Directorno data₹166.82m12.33%
₹ 30.6b
Vishal Baid
President of Corporate Sales & Marketing3.1yrs₹18.39m1.66%
₹ 4.1b
P. Rastogi
Assistant Vice President of Finance & Accountsno datageen gegevensgeen gegevens
Hemant Bhalla
Senior Vice President of Domestic Sales & Marketingno data₹5.79mgeen gegevens
Pankaj Gupta
President of R&Dno data₹5.61mgeen gegevens
Manish Sardana
President of Sales & Marketing - Indiano data₹8.61mgeen gegevens
6.9yrs
Gemiddelde duur
56yo
Gemiddelde leeftijd

Ervaren management: Het managementteam van POLYMED is doorgewinterd en ervaren (gemiddelde ambtstermijn van 6.9 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Himanshu Baid
CEO, MD & Director30.2yrs₹171.78m11.59%
₹ 28.7b
Jugal Baid
Founder & Non Executive Director30.2yrs₹1.43m2.25%
₹ 5.6b
Rishi Baid
Joint MD & Executive Director30.2yrs₹166.82m12.33%
₹ 30.6b
Vimal Bhandari
Non-Executive Independent Directorless than a yeargeen gegevensgeen gegevens
Amit Khosla
Non-Executive Independent Director4.9yrs₹1.60mgeen gegevens
Vishal Gupta
Independent Directorless than a yeargeen gegevensgeen gegevens
Devendra Mehta
Non-Executive Independent Chairman20yrs₹1.63mgeen gegevens
Mukulika Baid
Non-Executive Director10.8yrs₹1.43m3.02%
₹ 7.5b
Sonal Mattoo
Non-Executive Independent Director4.8yrs₹1.45mgeen gegevens
Alessandro Balboni
Non-Executive Non Independent Director7yrs₹29.90mgeen gegevens
Ambrish Mithal
Independent Director3.1yrs₹1.45mgeen gegevens
7.0yrs
Gemiddelde duur
63yo
Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van POLYMED wordt beschouwd als ervaren (gemiddelde ambtstermijn 7 jaar).

Bedrijfsanalyse en status van financiële gegevens

GegevensLaatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse2025/05/22 23:12
Aandelenkoers aan het einde van de dag2025/05/22 00:00
Inkomsten2025/03/31
Jaarlijkse inkomsten2025/03/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

PakketGegevensTijdframeVoorbeeld Amerikaanse bron *
Financiële gegevens bedrijf10 jaar
  • Resultatenrekening
  • Kasstroomoverzicht
  • Balans
Consensus schattingen analisten+3 jaar
  • Financiële prognoses
  • Koersdoelen analisten
Marktprijzen30 jaar
  • Aandelenprijzen
  • Dividenden, splitsingen en acties
Eigendom10 jaar
  • Top aandeelhouders
  • Handel met voorkennis
Beheer10 jaar
  • Leiderschapsteam
  • Raad van bestuur
Belangrijkste ontwikkelingen10 jaar
  • Bedrijfsaankondigingen

* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren, zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen voor het gebruik van onze rapporten en tutorials op Youtube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Poly Medicure Limited wordt gevolgd door 9 analisten. 6 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

AnalistInstelling
Karan KhannaAmbit Capital
Sunita VaidyanathanBrics Securities Limited
Rashmi Sancheti ShettyDolat Capital Market Pvt. Ltd.